Bio-IT World September 21, 2023
Over 900 genes have been implicated in the resistance of tumors to platinum-based chemotherapy that map to many different cellular pathways, thwarting efforts to identify a biomarker to predict refractoriness. Attacking these complex molecular phenotypes requires moving to next-generation molecular diagnostics capable of recognizing different networks of proteins that collectively describe, in advance, all cancer patients who will not respond to the standard first-line treatment, says Amanda Paulovich, M.D., Ph.D., professor and Aven Foundation Endowed Chair at Fred Hutchinson Cancer Center.
In fact, she and her colleagues have succeeded in using mass spectrometry to identify a 64-protein signature to predict the subset of patients with high-grade serous ovarian cancer (HGSOC) who are unlikely to respond to chemotherapy—and...
Today's Sponsors
Today's Sponsor